InflaRx NV
NASDAQ:IFRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
InflaRx NV
Cash from Financing Activities
InflaRx NV
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InflaRx NV
NASDAQ:IFRX
|
Cash from Financing Activities
€33.3m
|
CAGR 3-Years
158%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Financing Activities
-€52.9m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Financing Activities
-€5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Financing Activities
€97.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash from Financing Activities
-€40.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Cash from Financing Activities
€53.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
InflaRx NV
Glance View
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
See Also
What is InflaRx NV's Cash from Financing Activities?
Cash from Financing Activities
33.3m
EUR
Based on the financial report for Dec 31, 2025, InflaRx NV's Cash from Financing Activities amounts to 33.3m EUR.
What is InflaRx NV's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
29%
Over the last year, the Cash from Financing Activities growth was 8 520%. The average annual Cash from Financing Activities growth rates for InflaRx NV have been 158% over the past three years , 29% over the past five years .
